Please login to the form below

axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

Kite and Oxford BioTherapeutics sign oncology research pact

The main focus of that deal was Kite’s Yescarta (axicabtagene ciloleucel), the company’s first CAR-T therapy, which was approved in October 2017 for the treatment of adults with

Latest news

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

In the phase 2 ZUMA-12 study, after a single infusion of Yescarta (axicabtagene ciloleucel), 85% of LBCL patients achieved a response, while 74% of patients achieved a complete response.
Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.
GSK pays $50m upfront to tap Immatics’ cell therapy platform

Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to
FDA begins speedy review of BMS’ CAR-T liso-cel

If it does receive approval, liso-cel will come onto the market after rival Novartis’ Kymriah (tisangenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel).
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene ciloleucel) is available for the treatment of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.

More from news
Approximately 1 fully matching, plus 42 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Senior Account Manager: Competitive

Account Director – Creative Healthcare Communications: Competative

Medical Editor: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...